Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02592772 · ClinicalTrials.gov registry record · NA
Manipulating Tobacco Constituents in Male Menthol Smokers
A NA study, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 118
- Enrollment target
NCT02592772: Completed NA study, sponsored by UConn Health.
NCT02592772 is a NA study that has completed, run by UConn Health. The registered enrollment target is 118 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02592772, a NA study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 118 participants
- Enrollment target
Study Summary
This study examines the potential effect of reducing nicotine content or menthol or both in men. It will also examine whether there are gender differences in manipulating tobacco flavors and nicotine concentrations in cigarettes on smoking behavior.
Primary Outcome
Data analyses will include subjects from this study matched to female subjects from the parent study.
Interventions
- OTHER Reduced Nicotine Non-Menthol (RNC)
- OTHER Reduced Nicotine Menthol (RNC-Men)
- OTHER Conventional Nicotine Non-Menthol (CN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2016-02-04 |
| Est. Completion | 2019-06 |
| Phase | NA |
What the finished NCT02592772 record still lists
NCT02592772 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Reduced Nicotine Non-Menthol (RNC) is the first listed.
NCT02592772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02592772 about?
NCT02592772 is a clinical study titled "Manipulating Tobacco Constituents in Male Menthol Smokers". This study examines the potential effect of reducing nicotine content or menthol or both in men. It will also examine whether there are gender differences in manipulating tobacco flavors and nicotine concentrations in cigarettes on smoking behavior.
What is the current status of trial NCT02592772?
This trial is currently completed. It is a NA study. The enrollment target is 118 participants. The study started on 2016-02-04. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02592772?
The interventions under investigation include: Reduced Nicotine Non-Menthol (RNC) (OTHER), Reduced Nicotine Menthol (RNC-Men) (OTHER), Conventional Nicotine Non-Menthol (CN) (OTHER).
Who is sponsoring clinical trial NCT02592772?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02592772's enrollment target sits among peer trials
118 803rd of 2000 higher than 1,194 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI